Investors
MolMed at the 22nd American Society of Gene and Cell Therapy (ASGCT) congress on continuous innovation in the production of viral vectors for clinical use.
MolMed at the 22nd American Society of Gene and Cell Therapy (ASGCT) congress on continuous innovation in the production of viral vectors for clinical use. ▾
Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.